COMUNICADO: Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing M

 

COMUNICADO: Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing M

Publicado 24/06/2017 19:23:32CET

DARMSTADT, Germany, June 24, 2017 /PRNewswire/ --

- New data builds on company's longstanding commitment to MS 

Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 3rd Congress of the European Academy of Neurology (EAN), taking place from June 24-27, in Amsterdam, the Netherlands. Merck will present a total of 12 abstracts on multiple sclerosis (MS), including studies evaluating Rebif(R) (interferon beta-1a) as well as efficacy and safety data on the use of MAVENCLAD(TM) (Cladribine Tablets), Merck's short-course oral therapy recently recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) in patients with relapsing MS.

(Logo: http://photos.prnewswire.com/prnh/20170421/492737LOGO )

Data being presented at the Congress will provide further insights into the proposed mode of action of Cladribine Tablets, which is thought to selectively target and discontinuously reduce lymphocytes which may be integral to the pathological process of MS.

On 23 June, the Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion on the use of Cladribine Tablets for highly active relapsing MS, and this recommendation has been passed on to the EC to make the final decision on the Marketing Authorization Application (MAA) later this year.

"We are pleased with the recent CHMP positive opinion, which takes Cladribine Tablets a step closer to potentially benefitting patients with this debilitating disease," said Luciano Rossetti, Head of Global R&D for the biopharma business of Merck. "The data presented at EAN provide a detailed characterization of the effect of Cladribine Tablets on B and T lymphocytes in patients followed for up to eight years and provide further support for the use of Cladribine Tablets in patients with relapsing MS."

Attendees can learn more about Merck's programmes, pipeline and activities in neurology by visiting our medical booth B30.

The following abstracts have been accepted for presentation at the EAN Congress 2017:

(CONTINUA)

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies